We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+33.89%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.72B
AUM Growth
-$71.4M
Cap. Flow
-$452M
Cap. Flow %
-16.6%
Top 10 Hldgs %
41.91%
Holding
86
New
16
Increased
22
Reduced
27
Closed
9
Avg Time Held
2.6 years
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1.1 years

Top Buys

Rank Stock Value
1
SLN icon
Silence Therapeutics
SLN
+$44.1M
2
KROS icon
Keros Therapeutics
KROS
+$32.8M
3
FDMT icon
4D Molecular Therapeutics
FDMT
+$32.2M
4
CI icon
Cigna
CI
+$21.5M
5
IMNM icon
Immunome
IMNM
+$20.5M

Top Sells

Rank Stock Value
1
IMGN icon
Immunogen Inc
IMGN
+$487M
2
RYZB icon
RayzeBio, Inc. Common Stock
RYZB
+$115M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$67.7M
4
KRYS icon
Krystal Biotech
KRYS
+$31.2M
5
CTLT icon
CATALENT, INC.
CTLT
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.54%
2 Industrials 2.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KRYS icon
1
Krystal Biotech
KRYS
$9.79B
$268M 9.85%
1,508,250
-224,939
-13% -$31.2M
2018 Q4
21 quarters
FOLD icon
2
DELISTED
Amicus Therapeutics
FOLD
$156M 5.73%
13,257,286
-1,571,035
-11% -$20.1M
2013 Q2
43 quarters
IMNM icon
3
Immunome
IMNM
$2.03B
$121M 4.43%
4,889,554
+1,010,139
+26% +$20.5M
2023 Q4
1 quarter
SRRK icon
4
Scholar Rock
SRRK
$4.82B
$114M 4.18%
6,419,610
+17,105
+0.3% +$269K
2018 Q2
23 quarters
FATE icon
5
Fate Therapeutics
FATE
$232M
$96.7M 3.55%
13,169,057
– –
2015 Q2
35 quarters
RGNX icon
6
Regenxbio
RGNX
$454M
$95.9M 3.52%
4,551,556
+790,866
+21% +$14.1M
2017 Q1
28 quarters
DCPH icon
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$83.3M 3.06%
5,296,643
+495,103
+10% +$7.62M
2017 Q3
26 quarters
KYMR icon
8
Kymera Therapeutics
KYMR
$8.88B
$69.7M 2.56%
1,734,089
-89,867
-5% -$3.22M
2020 Q3
14 quarters
ADCT icon
9
ADC Therapeutics
ADCT
$185M
$68.6M 2.52%
15,269,217
-59,100
-0.4% -$218K
2020 Q2
15 quarters
STOK icon
10
Stoke Therapeutics
STOK
$1.5B
$68.5M 2.51%
5,073,049
+2,447,543
+93% +$14.8M
2019 Q2
19 quarters
AUGX icon
11
DELISTED
Augmedix, Inc. Common Stock
AUGX
$67M 2.46%
16,380,327
– –
2021 Q4
9 quarters
NRIX icon
12
Nurix Therapeutics
NRIX
$2.59B
$65.9M 2.42%
4,483,016
+1,226,497
+38% +$13.2M
2020 Q3
14 quarters
BHVN icon
13
Biohaven
BHVN
$1.65B
$63.6M 2.34%
1,163,241
-281,124
-19% -$13.9M
2023 Q3
2 quarters
BEAM icon
14
Beam Therapeutics
BEAM
$2.44B
$62.1M 2.28%
1,879,617
+449,834
+31% +$14M
2020 Q1
16 quarters
ZYME icon
15
Zymeworks
ZYME
$1.78B
$58.5M 2.15%
5,560,798
-229,432
-4% -$2.55M
2020 Q1
16 quarters
LIVN icon
16
LivaNova
LIVN
$4.19B
$58.1M 2.13%
1,037,780
-99,288
-9% -$5.16M
2021 Q1
12 quarters
STTK icon
17
Shattuck Labs
STTK
$535M
$50.2M 1.84%
5,615,489
-4,425
-0.1% -$40.5K
2020 Q4
13 quarters
ALXO icon
18
ALX Oncology
ALXO
$124M
$48.2M 1.77%
4,326,509
+667,245
+18% +$9.37M
2020 Q3
14 quarters
NGNE icon
19
Neurogene
NGNE
$444M
$47.6M 1.75%
935,252
-11,645
-1% -$389K
2019 Q4
17 quarters
AKRO icon
20
DELISTED
Akero Therapeutics
AKRO
$47M 1.72%
1,858,702
+749,226
+68% +$18M
2019 Q2
19 quarters
ABSI icon
21
Absci
ABSI
$1.5B
$46.9M 1.72%
8,253,316
+222,222
+3% +$1M
2021 Q3
10 quarters
PLRX icon
22
Pliant Therapeutics
PLRX
$54.7M
$46.1M 1.69%
3,097,220
+400,572
+15% +$6.61M
2020 Q2
15 quarters
SLN icon
23
Silence Therapeutics
SLN
$558M
$43.8M 1.61%
+2,027,669
New +$44.1M
2024 Q1
0 quarters
IDYA icon
24
IDEAYA Biosciences
IDYA
$3.27B
$40.5M 1.49%
922,678
-13,185
-1% -$567K
2023 Q4
1 quarter
FDMT icon
25
4D Molecular Therapeutics
FDMT
$674M
$40.2M 1.48%
+1,261,427
New +$32.2M
2024 Q1
0 quarters
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2024 Portfolio in Review

As of Q1 2024, Redmile Group held 86 positions worth $2.72B, down 2.6% from $2.8B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $452M in Q1 2024, closing 9 positions and reducing 27 holdings. Its most notable exit was Immunogen Inc, an estimated $487M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in Silence Therapeutics worth $43.8M.

  • Redmile Group's largest Q1 2024 buy was Silence Therapeutics: 2,027,669 shares worth $43.8M.
  • Redmile Group added most to Immunome in Q1 2024, an estimated $20.5M increase.
  • Redmile Group's biggest Q1 2024 reduction was Krystal Biotech, cutting an estimated $31.2M.
  • Redmile Group fully exited Immunogen Inc in Q1 2024, selling an estimated $487M.
  • Redmile Group's ten largest holdings make up 42% of its $2.72B portfolio in Q1 2024.
  • Redmile Group opened 16 new positions and closed 9 in Q1 2024.
  • Redmile Group's portfolio value fell 2.6% quarter-over-quarter to $2.72B.

Based on Redmile Group's 13F filing for Q1 2024, filed 15 May 2024.